Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, agosto 27
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Crescent Biopharma Inc
CBIO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$18.02
al cierre: Aug 27, 5:00 PM EST
$18.02
N/A
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Crescent Biopharma Financials
Crescent Biopharma (CBIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of $(4.93) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of $(19.63) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses of $(19.74) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q3 EPS $(1.27) Beats $(1.98) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.98) by 35.92 percent.
Benzinga Newsdesk
PRO
Crescent Biopharma Q2 EPS $(4.93) Misses $(1.11) Estimate, Cash Balance Of $152.6M
Benzinga Newsdesk
PRO
Catalyst Biosciences Q2 EPS $1.64 Up From $(0.64) YoY
Catalyst Biosciences (NASDAQ:CBIO) reported quarterly earnings of $1.64 per share. This is a 356.25 percent increase over losses of $(0.64) per share from the same period last year.
Benzinga Newsdesk
Privacy Manager